- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03202992
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
February 5, 2019 updated by: Antiva Biosciences
Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Topical ABI-1968 in Subjects With Anal High-Grade Squamous Intraepithelial Lesions (aHSIL)
This study evaluates the use of ABI-1968, a topical cream, in the treatment of anal precancerous lesions in adults with and without human immunodeficiency virus (HIV) infection.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
57
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Darlinghurst
-
Sydney, Darlinghurst, Australia, 2010
- Research Center
-
-
-
-
California
-
San Francisco, California, United States, 94115
- Research Center
-
-
Florida
-
Orlando, Florida, United States, 32803
- Research Center
-
-
Illinois
-
Chicago, Illinois, United States, 60614
- Research Center
-
-
New York
-
New York, New York, United States, 10011
- Research Center
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Female or male subjects, at least 27 years old.
- Confirmed diagnosis of intra-anal HSIL at least 3 months prior to screening and confirmed by histopathology (with p16 positive staining)
- Intra-anal HSIL are visible and evaluable by HRA at the time of screening, and no lesion(s) is suspicious for invasive cancer.
- For HIV-positive subjects, CD4 count must be at least 200/mm3 with undetectable (<50 copies/mL) viral load within the 3 months prior to enrollment. Subjects must be on a stable regimen of antiretroviral drugs for the 3 months prior to enrollment.
Exclusion Criteria:
- Women who are pregnant, plan to become pregnant in the next 3 months, or lactating females.
- Received topical treatment or ablative procedures for aHSIL in the 6 months prior to enrolment.
- History of cancer, including anal cancer (with the exception of basal cell or squamous cell carcinoma of the skin), or currently undergoing treatment for any skin cancer.
- History of genital herpes with > 3 outbreaks per year.
- Plan to have excision or ablation of the lesion(s) within 3 months of enrolment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose 1 -Single Ascending Dose (SAD)
SAD Dose Level 1 of ABI-1968 topical cream applied on Day 1 of the study
|
Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
|
Experimental: Dose 2 -Single Ascending Dose (SAD)
SAD Dose Level 2 of ABI-1968 topical cream applied on Day 1 of the study
|
Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
|
Experimental: Dose 3 -Single Ascending Dose(SAD)
SAD Dose Level 3 of ABI-1968 topical cream applied on Day 1 of the study
|
Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
|
Experimental: Dose 4 -Single Ascending Dose(SAD)
SAD Dose Level 4 of ABI-1968 topical cream applied on Day 1 of the study
|
Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
|
Experimental: Dose 5 -Single Ascending Dose(SAD)
SAD Dose Level 5 of ABI-1968 topical cream applied on Day 1 of the study
|
Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
|
Experimental: Dose 1 - Multiple Ascending Dose(MAD)
MAD Dose Level 1 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
|
Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
|
Experimental: Dose 2 -Multiple Ascending Dose(MAD)
MAD Dose Level 2 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
|
Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
|
Experimental: Dose 3 -Multiple Ascending Dose(MAD)
MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
|
Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
|
Experimental: Multiple Ascending Dose (MAD) Cohort Expansion
MAD Cohort Expansion of ABI-1968 applied at Day 1, Day 8, Day 15, Day 22 and Day 29
|
Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
|
Experimental: Dose 4-Multiple Ascending Dose(MAD)
MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
|
Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of aHSIL
Time Frame: SAD portion is 29 days/MAD portion is 84 days
|
Number of participants with Adverse Events related to treatment
|
SAD portion is 29 days/MAD portion is 84 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systemic exposure to ABI-1968 Topical Cream following topical application to the anal canal.
Time Frame: SAD portion is 29 days/MAD portion is 84 days
|
Plasma concentrations of ABI-1968 over time
|
SAD portion is 29 days/MAD portion is 84 days
|
Histopathology of areas with biopsy-proven disease following single and multiple doses of ABI-1968 Topical Cream.
Time Frame: SAD portion is 29 days/MAD portion is 84 days
|
Number of subjects with complete and or partial regression of aHSIL by High Resolution Anoscopy (HRA) and histopathology
|
SAD portion is 29 days/MAD portion is 84 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Clinical Operations, Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may use the contacts provided below.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 11, 2017
Primary Completion (Actual)
February 4, 2019
Study Completion (Actual)
February 4, 2019
Study Registration Dates
First Submitted
June 24, 2017
First Submitted That Met QC Criteria
June 27, 2017
First Posted (Actual)
June 29, 2017
Study Record Updates
Last Update Posted (Actual)
February 7, 2019
Last Update Submitted That Met QC Criteria
February 5, 2019
Last Verified
February 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Virus Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Uterine Cervical Diseases
- Uterine Diseases
- Disease Attributes
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- DNA Virus Infections
- Intestinal Neoplasms
- Rectal Diseases
- Tumor Virus Infections
- Colorectal Neoplasms
- Precancerous Conditions
- Neoplasms, Squamous Cell
- Rectal Neoplasms
- Anus Diseases
- Uterine Cervical Dysplasia
- Carcinoma in Situ
- Infections
- Communicable Diseases
- Carcinoma, Squamous Cell
- Anus Neoplasms
- Papillomavirus Infections
- Papilloma
- Squamous Intraepithelial Lesions of the Cervix
Other Study ID Numbers
- ABI-1968-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infection
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Allegheny Singer Research Institute (also known...Active, not recruitingHIV Infections | HIV-1-infection | HIV I InfectionUnited States
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
Rockefeller UniversityCompletedHIV Infection | Healthy Volunteers | HIV-1 InfectionUnited States
-
Erasmus Medical CenterRecruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
Erasmus Medical CenterActive, not recruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
AIDS Healthcare FoundationUniversity of California, Los AngelesCompleted
-
Merck Sharp & Dohme LLCCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal AntibodyUnited States
Clinical Trials on ABI-1968
-
Antiva BiosciencesCompletedCervical Cancer | Cervical Intraepithelial Neoplasia | CIN | Human Papilloma Virus | Cervical Dysplasia | HSIL of Cervix | Cervical Neoplasm | HSIL | High-Grade Squamous Intraepithelial Lesions | High-grade Cervical Intraepithelial NeoplasiaUnited States, Australia
-
Antiva BiosciencesCompletedCervical Cancer | Human Papilloma Virus | HSIL, High Grade Squamous Intraepithelial Lesions | Cervical Dysplasia | HSIL of Cervix | High-Grade Cervical Intraepithelial Neoplasia | HIV Negative | CIN - Cervical Intraepithelial Neoplasia | Cervical NeoplasmSouth Africa
-
Antiva BiosciencesTerminatedHIV Infection | Anal Cancer | Human Papilloma Virus Infection | HSIL, High-Grade Squamous Intraepithelial Lesions | Anus NeoplasmUnited States, Australia
-
Assembly BiosciencesCompletedChronic Hepatitis BNew Zealand
-
Assembly BiosciencesCompletedChronic Hepatitis BKorea, Republic of, Australia, United States, Hong Kong, United Kingdom, China, New Zealand
-
Assembly BiosciencesCompletedChronic Hepatitis BUnited States
-
Assembly BiosciencesCompletedChronic Hepatitis BNew Zealand
-
Antiva BiosciencesRecruitingCervical Intraepithelial NeoplasiaAustralia, South Africa
-
CelgeneCelgene CorporationTerminatedAdvanced Solid TumorsUnited States
-
Mario Negri Institute for Pharmacological ResearchBayerCompleted